Servier buys a biotech company Symphogen

French pharmaceutical company Servier announced the acquisition of Danish Symphogen, which will allow it to strengthen the portfolio immunologicheskikh drugs. Financial terms of the deal were not disclosed, wrote FiercePharma.

After closing they will get the rights to several experimental drugs based on antibodies, which are at different stages of development. Under the terms of the agreement, Symphogen will become an independent unit within the Servier will develop further monoclonal antibodies.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]